Servier announces an increase in turnover for 2015-2016
Growth bolstered by strong international performance
Suresnes, France – 7 February 2017 – Servier, France’s second largest pharmaceutical company, independent and governed by a foundation, has announced year-on-year growth of 2.7% for 2015-16. Turnover amounts to €4 billion, of which €2.8 billion come from Servier’s brand drugs and €1.2 billion from generics.
The net profit is €188 million, accounting for 5% of turnover.
This growth can be explained by
- a strong international performance for Servier’s drugs
- a significant increase for generics in all territories (France, Europe, Commonwealth of Independent States and Brazil).
The internationalization of the group is still progressing: global turnover excluding France amounts to €3.1 billion, up 8%. A strong presence as well as long-standing investments, especially in emerging countries, gives the Group a key position in many countries. China and Russia each represent 8% of global turnover, Canada 5% and Italy 3%. Romania, which posted the strongest growth, comes in fifth position.
“Our strong international growth is also reflected in the group’s proactive partnership policy, which was particularly active last year,” said Olivier Laureau, President of Servier. “In recent years, the group has entered over 40 partnerships with world-class partners such as Pfizer, Novartis, Amgen, Taiho, and several innovative biotechs such as Intarcia, Cellectis and GeNeuro. 7 of these partnerships have been signed in the last 18 months.”
Oncology has become one of the group’s main growth areas in recent years, doubling its turnover in just one year. This reflects the importance of innovations carried by the Group.
In 2016, Servier was confirmed as Europe’s second largest company in cardiology. Its balanced and diversified portfolio provides Servier with a growth mainly ensured by its top products Coversyl, Diamicron, Daflon, Preterax and Vastarel, which posted 5% growth in 2015-2016.
The generics portfolio includes over 900 specialties in 19 therapeutic domains, in line with the commitment of Servier to offer to the highest number of patients the drugs they need. Biosimilars have gained an increased share of the growth, having doubled in turnover compared to last year.
The weight of the domestic market (France), for Servier’s drugs and generics, represents 22.6% of global turnover, mainly carried by the generics, while Servier’s drugs have yet again decreased to €M205, despite increases in sales volumes. The group has maintained its value creation in France by continuing to invest heavily in production and R&D, and as a result, France accounts for 50% of Servier’s total payroll. The group contributes to the French pharmacy and fine chemistry trade balance surplus to the tune of €1,426 million.
Thanks to its organization as an independent company, with no shareholders, Servier invests all its profits in therapeutic progress to serve patient needs.
Servier is an international pharmaceutical company governed by a foundation and headquartered in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.
More information: www.servier.com
Servier External Communications
Tel: +33 1 5572 6037